From 2011 to 2017 there was a 19.8 percent increase in the abortion rate in the state of Wyoming, compared to a decrease of 62.9 percent in Delaware. This statistic shows the percentage change in the abortion rate in the U.S. from 2011 and 2017, by state.

During the period between 2011 and 2022 the rate of abortions performed in teenagers under 20 years old per 1,000 women in Spain showed an overall decreasing trend. The figure went from a total of 13.68 abortions per 1,000 women in 2011 to 8.54 abortions per 1,000 women in 2022. During that period, the rate of births to teenage mothers in Spain was also decreasing.

The number of abortions performed per thousand women in Spain reached 12.5 in 2011, the maximum value recorded in the period studied. From 2011 to 2016 there was a gradual decline in the abortion rate, dropping to 10.4 abortions per thousand women. However, there has been an increase in the rate of abortions since then, reaching 11.68 per thousand women in 2022. An exception was observed in 2020 when this figure decreased. In that year, Catalonia was the Spanish region with the highest abortion rate, followed by Madrid, and the Balearic Islands.

Teenage abortion rates

In 2022, the age group that registered the highest abortion rate was that of women from 20 to 24 years old, with more than 18 voluntary abortions performed per thousand women. The abortion rate in women under 20 amounted to 8.5 abortions per thousand women, the second-lowest rate after that of women over 39 years. In addition, the abortion rate in teenage women has generally decreased in the past few years, dropping from 13.7 in 2011 to 8.5 in 2022.

Attitudes towards abortion

During a survey carried out in Spain in 2023, around 37 percent of respondents stated that abortion should be legal in all cases, while another 36 percent was of the opinion that it should be legal in most cases. In contrast, four percent of interviewees thought abortion should be always illegal, with an additional 12 percent stating that it should be illegal in most cases.

Note: The data include all types of abortions (medical/pharmaceutical, vacuum/mini, and surgical).Data sources: Statistical Yearbook of The Republic of Belarus: 2011/National Statistical Committee of the Republic of Belarus, Minsk, 2011, p. 228 (in Russian), available: http://belstat.gov.by/homep/ru/publications/archive/2011.php; Demographic Yearbook of Russia 2010: Statistical Handbook/Federal State Statistics Service, Moscow, 2010, p. 172 (in Russian), available: http://www.gks.ru/wps/wcm/connect/rosstat/rosstatsite/main/publishing/catalog/statisticCollections/doc_1137674209312; Statistical Yearbook of Ukraine: 2010/State Statistics Service of Ukraine, 2011, p. 465 (in Ukrainian), available: http://www.ukrstat.gov.ua/.

During the period between 2011 and 2022 the rate of abortions performed per 1,000 women in the Community of Madrid in Spain saw an overall decrease. The figure went from a total of 15.4 abortions per 1,000 women in 2011 to 12.89 abortions per 1,000 women in 2022. That year, the abortion rate among under 20 year olds amounted to 8.54 procedures per 1,000 women in Spain.

In the Northwest region of the U.S. between 2011 and 2017, there was a net increase in the number of abortion clinics, with 59 new clinics, versus a decrease of 33 in the Midwest. The statistic illustrates the change in the number of abortion clinics in the U.S. from 2011 to 2017, by region.

Termination of pregnancy (abortion) aged 15-17 years of Talas sank by 53.85% from 3.9 per 1000 women of the same age in 2011 to 1.8 per 1000 women of the same age in 2012. Since the 5.00% jump in 2010, termination of pregnancy (abortion) aged 15-17 years slumped by 14.29% in 2012.

BackgroundThe WHO estimates that 13% of maternal mortality is due to unsafe abortion, but challenges with measurement and data quality persist. To our knowledge, no systematic assessment of the validity of studies reporting estimates of abortion-related mortality exists. Study DesignTo be included in this study, articles had to meet the following criteria: (1) published between September 1st, 2000-December 1st, 2011; (2) utilized data from a country where abortion is “considered unsafe”; (3) specified and enumerated causes of maternal death including “abortion”; (4) enumerated ≥100 maternal deaths; (5) a quantitative research study; (6) published in a peer-reviewed journal. Results7,438 articles were initially identified. Thirty-six studies were ultimately included. Overall, studies rated “Very Good” found the highest estimates of abortion related mortality (median 16%, range 1–27.4%). Studies rated “Very Poor” found the lowest overall proportion of abortion related deaths (median: 2%, range 1.3–9.4%). ConclusionsImprovements in the quality of data collection would facilitate better understanding global abortion-related mortality. Until improved data exist, better reporting of study procedures and standardization of the definition of abortion and abortion-related mortality should be encouraged.

Objective: To test whether there is an association between abortion legislation and maternal mortality outcomes after controlling for other factors thought to influence maternal health. Design: Population-based natural experiment. Setting and data sources: Official maternal mortality data from 32 federal states of Mexico between 2002 and 2011. Main outcomes: Maternal mortality ratio (MMR), MMR with any abortive outcome (MMRAO) and induced abortion mortality ratio (iAMR). Independent variables: Abortion legislation grouped as less (n=18) or more permissive (n=14); constitutional amendment protecting the unborn (n=17); skilled attendance at birth; all-abortion hospitalisation ratio; low birth weight rate; contraceptive use; total fertility rates (TFR); clean water; sanitation; female literacy rate and intimate-partner violence. Main results: Over the 10-year period, states with less permissive abortion legislation exhibited lower MMR (38.3 vs 49.6; p<0.001), MMRAO (2.7 vs 3.7; p<0.0...

During the period between 2011 and 2022 the number of voluntary pregnancy terminations performed in Spain saw an overall decreasing trend. The figure went from a total of 118,600 abortions in 2011 to 98,316 abortions in 2022. During that period, the abortion rate among under 20 year olds in the European country was also decreasing.

BackgroundIn February 2011, an Ohio law took effect mandating use of the United States Food and Drug Administration (FDA)-approved protocol for mifepristone, which is used with misoprostol for medication abortion. Other state legislatures have passed or enacted similar laws requiring use of the FDA-approved protocol for medication abortion. The objective of this study is to examine the association of this legal change with medication abortion outcomes and utilization.Methods and FindingsWe used a retrospective cohort design, comparing outcomes of medication abortion patients in the prelaw period to those in the postlaw period. Sociodemographic and clinical chart data were abstracted from all medication abortion patients from 1 y prior to the law’s implementation (January 2010–January 2011) to 3 y post implementation (February 2011–October 2014) at four abortion-providing health care facilities in Ohio. Outcome data were analyzed for all women undergoing abortion at ≤49 d gestation during the study period. The main outcomes were as follows: need for additional intervention following medication abortion (such as aspiration, repeat misoprostol, and blood transfusion), frequency of continuing pregnancy, reports of side effects, and the proportion of abortions that were medication abortions (versus other abortion procedures). Among the 2,783 medication abortions ≤49 d gestation, 4.9% (95% CI: 3.7%–6.2%) in the prelaw and 14.3% (95% CI: 12.6%–16.0%) in the postlaw period required one or more additional interventions. Women obtaining a medication abortion in the postlaw period had three times the odds of requiring an additional intervention as women in the prelaw period (adjusted odds ratio [AOR] = 3.11, 95% CI: 2.27–4.27). In a mixed effects multivariable model that uses facility-months as the unit of analysis to account for lack of independence by site, we found that the law change was associated with a 9.4% (95% CI: 4.0%–18.4%) absolute increase in the rate of requiring an additional intervention. The most common subsequent intervention in both periods was an additional misoprostol dose and was most commonly administered to treat incomplete abortion. The percentage of women requiring two or more follow-up visits increased from 4.2% (95% CI: 3.0%–5.3%) in the prelaw period to 6.2% (95% CI: 5.5%–8.0%) in the postlaw period (p = 0.003). Continuing pregnancy was rare (0.3%). Overall, 12.6% of women reported at least one side effect during their medication abortion: 8.4% (95% CI: 6.8%–10.0%) in the prelaw period and 15.6% (95% CI: 13.8%–17.3%) in the postlaw period (p < 0.001). Medication abortions fell from 22% (95% CI: 20.8%–22.3%) of all abortions the year before the law went into effect (2010) to 5% (95% CI: 4.8%–5.6%) 3 y after (2014) (p < 0.001). The average patient charge increased from US$426 in 2010 to US$551 in 2014, representing a 16% increase after adjusting for inflation in medical prices. The primary limitation to the study is that it was a pre/post-observational study with no control group that was not exposed to the law.ConclusionsOhio law required use of a medication abortion protocol that is associated with a greater need for additional intervention, more visits, more side effects, and higher costs for women relative to the evidence-based protocol. There is no evidence that the change in law led to improved abortion outcomes. Indeed, our findings suggest the opposite. In March 2016, the FDA-protocol was updated, so Ohio providers may now legally provide current evidence-based protocols. However, this law is still in place and bans physicians from using mifepristone based on any new developments in clinical research as best practices continue to be updated.

This statistic shows the number of clinics providing abortions in U.S. states with the largest increases in clinics from 2011 to 2017. The number of abortion-providing clinics in New Jersey rose from 24 in 2011 to 41 in 2017.

There is evidence from the United States that the legalisation of abortion has led to a significant reduction in neonatal and infant mortality. However, no research to date has been able to disentangle between effects of improved access to abortion at the household- and cohort-levels; there is no evidence for developing countries; and existing studies of the impact of abortion legalisation on early life health in the United States are not unanimous. Nepal initiated a drastic abortion reform in 2002. Moreover, because abortion facilities were made available to the public, the change in the law was not purely de jure. This research will collect data on local availability of abortion services, which opened at different times over a two-year period across the country. Combined with existing data sources, this information will allow estimating the effect of improved access to abortion more precisely, holding constant a number of potentially confounding factors. It will also compare neonatal mortality occurrence between siblings born before and those born after the opening of a nearby legal abortion centre, compare the effect on boys and girls, and estimate whether there is any evidence of improved access to abortion leading to sex-selective abortions.

Postpartum and / or post-abortion contraceptive counseling and provision. National data and by provinces 2011.Data available on counseling and provision of postpartum and / or post-abortion contraceptives by health services (Baseline to be defined. Goal 90%)Source: Observatory of Sexual and Reproductive Health - https://www.ossyr.org.ar/indicadores.php#Datos-nacionales-sobre-consejer%C3%ADa-y-suministro-de-anticonceptivos-posparto-y/o-posaborto-por-los-servicios-de-saludOrganización Panamericana de la Salud. Ministerio de Salud de la Nación. Primer informe nacional de relevamiento epidemiológico SIP-Gestión: desarrollo e implementación a escala nacional de un sistema de información en salud.This dataset is just one of the many data visualizations on the Global Midwives Hub, a digital resource with open data, maps, and mapping applications (among other things), to support advocacy for improved maternal and newborn services, supported by the International Confederation of Midwives (ICM), UNFPA, WHO, and Direct Relief. de la mujer y perinatal en Argentina. Buenos Aires: OPS, 2013.

Unadjusted and adjusted odds ratio of factors associated with unsafe abortion in Nepal in 2011–2016 (N = 911).

This statistic shows the number of clinics providing abortions in U.S. states with the largest decreases in clinics from 2011 to 2017. In 2011, Texas had 46 abortion-providing clinics, however by 2017 that number had decreased to 21. Many of these states enacted restrictions or targeted regulations on abortion providers from 2011 to 2017.

PurposeTo determine whether 5-methylenetetrahydrofolate (MTHF) is more effective than folic acid supplementation in treatment of recurrent abortion in different MTHFR gene C677T and A1298C polymorphisms.MethodsA randomized, double blind, placebo-controlled trial conducted April 2011-September 2014 in recurrent abortion clinics in Tehran, Iran. The participants were women with three or more idiopathic recurrent abortion, aged 20 to 45 years. Two hundred and twenty eligible women who consented to participate were randomly assigned to receive either folic acid or 5-MTHF according to the stratified blocked randomization by age and the number of previous abortions. Participants took daily 1 mg 5-methylentetrahydrofolate or 1 mg folic acid from at least 8 weeks before conception to the 20th week of the pregnancy. The primary outcome was ongoing pregnancy rate at 20th week of pregnancy, and the secondary outcomes were serum folate and homocysteine at the baseline, after 8 weeks, and at the gestational age of 4, 8, 12, and 20 weeks, MTHFR gene C677T and A1298C polymorphisms.ResultsThere was no significant difference in abortion rate between two groups. Serum folate increased significantly in both groups over time; these changes were significantly higher in the group receiving 5-MTHF than the group receiving folic acid (value = 2.39, p